The anti-tumor activity of metformin is also exerted by interfering with nemo-like kinase (NLK), a member of the MAPK family, which carries out a relevant role in cell cycle progression and contributes to the oncogenesis of several neoplasms, including colon, prostate, lung, and hepatocellular cancer. This evidence concerns the gene NLK and neoplasm.